In FTC, PI3K/AKT activation is thought to arise from RAS mutations, inactivating mutations in the PTEN or RASL1 tumor suppressor genes, or by activating mutations in PIK3CA and AKT1 [9–11]. The gene discussed is AKT1; the disease is thyroid cancer, nonmedullary, 2.